المؤلفون: Kayisli, Umit A., Guzeloglu-Kayisli, Ozlem, Guzel, Elif, Arici, Aydin

المصدر: Gynecologic & Obstetric Investigation; May2013, Vol. 75 Issue 4, p235-242, 8p, 2 Diagrams, 3 Graphs

مصطلحات موضوعية: GENISTEIN, ISOFLAVONES, ESTRADIOL, CORONARY arteries, IMMUNOCYTOCHEMISTRY, ENDOTHELIAL cells

مستخلص: Background/Aims: Isoflavone genistein is a plant-derived compound structurally similar to estradiol, which behaves weakly estrogenic or anti-estrogenic in a cell- and concentration-dependent manner. Genistein has been hypothesized to have beneficial effects on vascular diseases, although the mechanism has been unclear. Here, we investigated whether genistein may play a role in atherogenesis by regulating human coronary artery endothelial cell (HCAEC) survival. Methods: HCAECs obtained from 48- to 53-year-old women (n = 3) were used and immunocytochemistry, cell proliferation assay and apoptosis assay were carried on HCAECs treated by genistein. Results: Immunocytochemistry confirmed that HCAECs in culture express predominantly ESR2. Cell proliferation assay revealed that following 72 h of genistein treatment, HCAEC proliferation decreased in a concentration-dependent (10^-10 to 10^-6M) manner compared to control (p < 0.01). The anti-proliferative effect of genistein is inhibited by estradiol. Genistein (10^-8M) also induced a time-dependent increase in the number of apoptotic HCAECs after 24-, 48- and 72-hourtreatments as detected by TUNEL and morphological analyses. Conclusion: These findings suggest that genistein acts as an anti-proliferative agent on HCAECs. The anti-proliferative and proapoptotic effects of genistein on vascular cells underlie the proposed anti-atherogenic and cardioprotective role of genistein. Copyright © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

: Copyright of Gynecologic & Obstetric Investigation is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Özkan, Sebiha¹ sozkan1972@yahoo.com, Arici, Aydin²

المصدر: Gynecologic & Obstetric Investigation. Feb2009, Vol. 67 Issue 2, p81-91. 11p. 4 Charts.

مصطلحات موضوعية: *ENDOMETRIOSIS, *FEMALE reproductive organ diseases, *INFERTILITY, *WOMEN'S health, *GYNECOLOGY

مستخلص: Endometriosis, defined as the presence of endometrial tissue outside the uterus, is a challenging condition associated with substantial morbidity. Management of endometriosis must be individualized according to the desired treatment outcome, whether it is relief of pain, improvement of fertility, or the prevention of recurrence. For alleviation of endometriosis-associated pain, medical treatment is generally successful, with no medical agent being more efficacious than another in spite of significantly differing side-effect profiles. Surgical therapy has also been demonstrated to reduce pain scores in comparison with expectant management, although conservative surgery has been frequently associated with recurrence. The efficacy of combination therapies still remains to be clarified. For treatment of endometriosis-associated infertility, suppressive medical treatment has been proven to be detrimental to fertility and should be discouraged, while surgery is probably efficacious for all stages. Controlled ovarian hyperstimulation with intrauterine insemination is recommended in early-stage and surgically corrected endometriosis. Combined surgery with GnRH analog treatment has been proposed to be first-line therapy, followed by IVF as second-line therapy in advanced cases. More rigorously designed randomized clinical trials focusing on the endocrinological, immunological, and genetic aspects of endometriosis are necessary to refine conclusions regarding the etiopathogenesis and therapeutic innovations of this perplexing disease. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]